Characteristics by subgroup
| Characteristics . | Prepandemic N = 936 . | Pandemic N = 347 . |
|---|---|---|
| Age (y) at initiation of 2L, n (%) | ||
| <65 | 489 (52.2) | 170 (49.0) |
| ≥65 | 447 (47.8) | 177 (51.0) |
| Sex, n (%) | ||
| Female | 364 (38.9) | 142 (40.9) |
| Race, n (%) | ||
| Black or African American | 68 (7.3) | 31 (8.9) |
| Asian | 6 (0.6) | 2 (0.6) |
| White | 744 (79.5) | 253 (72.9) |
| Other race | 102 (10.9) | 52 (15.0) |
| Unknown | 16 (1.7) | 9 (2.6) |
| Ethnicity, n (%) | ||
| Hispanic | 75 (8.0) | 32 (9.2) |
| Non-Hispanic | 831 (88.8) | 303 (87.3) |
| Unknown | 30 (3.2) | 12 (3.5) |
| Practice type, n (%) | ||
| Academic | 114 (12.2) | 42 (12.1) |
| Community | 822 (87.8) | 305 (87.9) |
| Year of initial diagnosis, n (%) | ||
| ≤2014 | 747 (79.8) | 169 (48.7) |
| 2015-2019 | 189 (20.2) | 160 (46.1) |
| ≥2020 | 0 (0.0) | 18 (5.2) |
| Follow-up time from initial diagnosis (mo), median (IQR) | 112.3 (77.4-155.7) | 91.9 (60.1-128.6) |
| Time from initial diagnosis to 2L initiation (mo), median (IQR) | 60.0 (33.5-98.1) | 73.0 (41.0-109.5) |
| Follow-up time from 2L initiation (mo), median (IQR) | 49.3 (28.9-69.1) | 18.1 (10.0-30.1) |
| ECOG performance status, n (%) | ||
| 0-1 | 636 (67.9) | 197 (56.8) |
| ≥2 | 33 (3.5) | 17 (4.9) |
| Unknown | 267 (28.5) | 133 (38.3) |
| Rai stage at diagnosis, n (%) | ||
| 0 | 241 (25.7) | 115 (33.1) |
| I | 200 (21.4) | 52 (15.0) |
| II | 91 (9.7) | 29 (8.4) |
| III/IV | 153 (16.3) | 55 (15.9) |
| Unknown | 251 (26.8) | 96 (27.7) |
| Cytogenetic risk,∗ n (%) | ||
| Low risk | 30 (3.2) | 14 (4.0) |
| High risk | 184 (19.7) | 100 (28.8) |
| Unknown | 722 (77.1) | 233 (67.1) |
| Bulky disease,† n (%) | ||
| Presence | 70 (7.5) | 23 (6.6) |
| Absence | 113 (12.1) | 32 (9.2) |
| Unknown | 753 (80.4) | 292 (84.1) |
| TP53, n (%) | ||
| Negative | 370 (39.5) | 191 (55.0) |
| Positive | 79 (8.4) | 43 (12.4) |
| Unknown | 487 (52.0) | 113 (32.6) |
| IGHV, n (%) | ||
| Unmutated | 112 (12.0) | 70 (20.2) |
| Mutated | 53 (5.7) | 28 (8.1) |
| Unknown | 771 (82.4) | 249 (71.8) |
| Characteristics . | Prepandemic N = 936 . | Pandemic N = 347 . |
|---|---|---|
| Age (y) at initiation of 2L, n (%) | ||
| <65 | 489 (52.2) | 170 (49.0) |
| ≥65 | 447 (47.8) | 177 (51.0) |
| Sex, n (%) | ||
| Female | 364 (38.9) | 142 (40.9) |
| Race, n (%) | ||
| Black or African American | 68 (7.3) | 31 (8.9) |
| Asian | 6 (0.6) | 2 (0.6) |
| White | 744 (79.5) | 253 (72.9) |
| Other race | 102 (10.9) | 52 (15.0) |
| Unknown | 16 (1.7) | 9 (2.6) |
| Ethnicity, n (%) | ||
| Hispanic | 75 (8.0) | 32 (9.2) |
| Non-Hispanic | 831 (88.8) | 303 (87.3) |
| Unknown | 30 (3.2) | 12 (3.5) |
| Practice type, n (%) | ||
| Academic | 114 (12.2) | 42 (12.1) |
| Community | 822 (87.8) | 305 (87.9) |
| Year of initial diagnosis, n (%) | ||
| ≤2014 | 747 (79.8) | 169 (48.7) |
| 2015-2019 | 189 (20.2) | 160 (46.1) |
| ≥2020 | 0 (0.0) | 18 (5.2) |
| Follow-up time from initial diagnosis (mo), median (IQR) | 112.3 (77.4-155.7) | 91.9 (60.1-128.6) |
| Time from initial diagnosis to 2L initiation (mo), median (IQR) | 60.0 (33.5-98.1) | 73.0 (41.0-109.5) |
| Follow-up time from 2L initiation (mo), median (IQR) | 49.3 (28.9-69.1) | 18.1 (10.0-30.1) |
| ECOG performance status, n (%) | ||
| 0-1 | 636 (67.9) | 197 (56.8) |
| ≥2 | 33 (3.5) | 17 (4.9) |
| Unknown | 267 (28.5) | 133 (38.3) |
| Rai stage at diagnosis, n (%) | ||
| 0 | 241 (25.7) | 115 (33.1) |
| I | 200 (21.4) | 52 (15.0) |
| II | 91 (9.7) | 29 (8.4) |
| III/IV | 153 (16.3) | 55 (15.9) |
| Unknown | 251 (26.8) | 96 (27.7) |
| Cytogenetic risk,∗ n (%) | ||
| Low risk | 30 (3.2) | 14 (4.0) |
| High risk | 184 (19.7) | 100 (28.8) |
| Unknown | 722 (77.1) | 233 (67.1) |
| Bulky disease,† n (%) | ||
| Presence | 70 (7.5) | 23 (6.6) |
| Absence | 113 (12.1) | 32 (9.2) |
| Unknown | 753 (80.4) | 292 (84.1) |
| TP53, n (%) | ||
| Negative | 370 (39.5) | 191 (55.0) |
| Positive | 79 (8.4) | 43 (12.4) |
| Unknown | 487 (52.0) | 113 (32.6) |
| IGHV, n (%) | ||
| Unmutated | 112 (12.0) | 70 (20.2) |
| Mutated | 53 (5.7) | 28 (8.1) |
| Unknown | 771 (82.4) | 249 (71.8) |
High cytogenetic risk defined as at least 1 of: del(17p) and/or TP53 mutation and/or IGHV unmutated; low cytogenetic risk defined as none of: del(17p) and/or TP53 mutation and/or IGHV unmutated; and unknown defined as at least 1 unknown test result and none of: del(17p) and/or TP53 mutation and/or IGHV unmutated.
Bulky disease is reported as documented in the electronic health records by the treating physician.